ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical ...

But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should ORIC Pharmaceuticals ...

Shares of ORIC stock opened at $7.03 on Thursday. The firm has a market cap of $499.32 million, a price-to-earnings ratio of -3.86 and a beta of 1.25. ORIC Pharmaceuticals has a 52-week low of $6. ...

In a report released on March 21, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with ...

Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report) today. The company’s shares opened ...

Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.

After hours: March 18 at 6:36:03 PM EDT Loading Chart for ORIC ...

Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...